Adam C. Berger, MD, FACS, Chief, Melanoma and Soft Tissue Surgical Oncology, Associate Director for Shared Resources at Rutgers Cancer…
Browsing: Melanoma and Skin
GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with…
GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with…
GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with…
GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with…
GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with…
GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with…
GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with…
Iván Márquez Rodas MD, Ph.D. of the Medical Oncology Department, Hospital Gregorio Marañon, Madrid, Spain Speaks about Highlight & Pivotal…
Douglas Johnson, MD, MSCI, associate professor of Medicine at Vanderbilt University Medical Center and clinical director of Melanoma at Vanderbilt-Ingram…
Adil Daud, MD Professor of Medicine at The University of California, San Francisco, Director of the Melanoma Clinical Research, and…
Professor Arthur D. Lander, M.D., Ph.D. of UCI University of California, Irvine speaks about Dynamics of nevus development implicate cell…
Alexander Stratigos, M.D., Professor of Dermatology/Or Investigator of the University of Athens Medical School at Andreas Sygros Hospital explains the…
Ana Maria Arance Fernandez, MD of Hospital ClÃnic de Barcelona, Barcelona, Spain speaks on her ESMO abstract – LBA44 -…
Alexander Eggermont, MD of Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay explains the ESMO 2020 abstract LBA46 -…
Omid Hamid MD Chief, Translational Research/Immuno-Oncology Director, Experimental Therapeutics Cedars Sinai Foundation discusses the Multi-Modality Management of Melanoma in the…
Craig Slingluff, MD of @UVACancerCenter answers the study design and what is next for phase III data for a melanoma…
Craig Slingluff, MD of @UVACancerCenter discusses the phase III data for a melanoma vaccine, seviprotimut-L. ____________ — MAVIS Study Identifies…
— MAVIS Study Identifies Most Responsive Patient Subpopulations, Supporting the Continued Study of Adjuvant Treatment in Localized Melanoma Patients –…
Viruses designed to kill cancer cells are already used to treat one skin cancer and are commonly studied in other…
John Fruehauf, MD disucsses whether the CheckMate 204 data will affect treatment selection in brain metastases
John Fruehauf, MD of UC Irvine Health discusses new first-line therapy for asymptomatic melanoma brain metastases. Â Â Â Â …
John Fruehauf, MD of UC Irvine Health explains clinicians could change the way they manage their patients by lowering doses…
John Fruehauf, MD provides insight on how to address toxicity that is causing colitis.
John Fruehauf, MD of UC Irvine Health discusses lowering toxicity through alternate dosing.
John Fruehauf, MD of UC Irvine Health presents whether data practice will change for clinicians.
John Fruehauf, MD of UC Irvine Health explains how INMC data has impacted surgical oncologists.
Michael B. Atkins at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology follows up on…
Keith T. Flaherty, M.D. Of Array BioPharma Discusses Updated Data From Phase 3 COLUMBUS Trial: Encorafenib Was The Agent Of…
Robert Rifkin MD Of US Oncology Research Discusses Measuring BCMA: Do Not Have To Wait For Relapse, We Know When…
Robert Rifkin MD Of US Oncology Research Discusses Trial Updates At ASCO: Approval Of Daratumumab In Combination With Revlimid Or…
Robert Rifkin MD Of US Oncology Research Discusses Isatuximab & Daratumumab: When You Add Isatuximab To Pomalidomide & Dexamethasone Outcomes…
Robert Rifkin MD Of US Oncology Research Discusses Connect MM Myeloma Disease Registry: This Is A Special Group Of Myeloma…
Dr. Michael Atkins MD Of Georgetown University Discusses Who Should Get Ipi:Nivo VS NIVO Monotherapy: Patients With Elevated LDH, BRAF…
Dr. Michael Atkins MD Of Georgetown University Discusses CHECKMATE-004 Trial Results: 57% Of Patients Were Alive At 4 Years, Treatment…
Alexander Guminski MD Of The University of Sydney Discusses Where Is Cemiplimab Best Placed: Deploying Early As A Stand Alone…
Alexander Guminski MD Of The University of Sydney Discusses Phase 2 Study Of Cemiplimab: Response Rate Of 49 Estimated PFS…
Elizabeth Buchbinder MD Of DFCI Discusses Mucosal Melanoma: Rare Form Of Melanoma With Much Lower Mutational Burden.
Omid Hamid MD @OmidHamidMD Of The Angeles Clinic Discusses First Line Melanoma Trial: Utilizes Microbiome Manipulation In Newly Diagnosed Patients…
Jessica Geiger MD Of The Cleveland Clinic Discusses Are There Therapies For Squamous Cell Carcinoma: PD-1 Inhibitor Approved For Metastatic…
Jessica Geiger MD Of The Cleveland Clinic Discusses KEYNOTE-630: Randomizing Patients To Get Either Pembrolizumab Or Placebo.
Jessica Geiger MD Of The Cleveland Clinic Discusses Recruiting Patients For KEYNOTE-630: Looking For Patients With High Risk Features Like…
Ahmad Tarhini Md, PhD of the Winship Cancer Center discusses the United States Intergroup E1609 A phase III randomized study…
Marcus Butler, MD discusses TBI-1301-Effect of minimal lymphodepletion prior to ACT with TBI-1301, NY-ESO-1 specific gene-engineered TCR-T cells, on clinical…
Multiple myeloma (MM) therapy has evolved rapidly in recent years, and is showing no sign of slowing. Here, Kenneth Anderson,…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Grant McArthur, MBBS, BMedSc, PhD,…
Great strides have been made in the treatment of advanced melanoma; these developments are now being translated into the adjuvant…
Melanoma that has metastasized to the brain is extremely high risk, and such metastasis is more likely in patients with…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Paolo Ascierto, MD, of the…
While treatments for melanoma have been steadily improving over recent years, patients with brain metastases have consistently had poor outcomes.…